Vinay Gudena

474 citations
18 papers · 181 indexed · h-index 6
Topics
Cancer Treatment and Pharmacology (6 papers)HER2/EGFR in Cancer Research (4 papers)Breast Cancer Treatment Studies (3 papers)

In The Last Decade

Vinay Gudena

17 papers receiving 174 citations

Peers

Vinay Gudena
Comparison fields: 5 of 50
  • Oncology 102
  • Molecular Biology 53
  • Pulmonary and Respiratory Medicine 40
  • Surgery 38
  • Pathology and Forensic Medicine 33
Replace Patricia Maeda with:
Patricia Maeda United States
S. Keith Anderson United States
Ayşegül Şahin Türkiye
J. Li United States
Hiroshi Nishimiya Japan
Sophie Shifman United States
Taner Korkmaz Türkiye
Gabit Alipov Japan
Akira Okimura Japan
Aikaterini Parasi Greece
Vinay Gudena relative to Patricia Maeda United States Patricia Maeda's profile →
Citations per field
00.5×10×15×19×
Patricia Maeda · 1×
Citations per year

Countries citing papers authored by Vinay Gudena

Since Specialization
Citations

This map shows the geographic impact of Vinay Gudena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vinay Gudena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vinay Gudena more than expected).

Fields of papers citing papers by Vinay Gudena

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vinay Gudena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vinay Gudena. The network helps show where Vinay Gudena may publish in the future.

Co-authorship network of co-authors of Vinay Gudena

This figure shows the co-authorship network connecting the top 25 collaborators of Vinay Gudena. A scholar is included among the top collaborators of Vinay Gudena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vinay Gudena. Vinay Gudena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 0
2 3
3 5
4 1
5 3
6 1
7 1
8 6
9 1
10 35
11 27
12 61
13 9
14 1
15
Primary testicular lymphoma and AIDS.
3
16 18
17 1
18 5

About Vinay Gudena

Vinay Gudena is a scholar working on Family Practice, Oncology and Cancer Research, having authored 18 papers that have together received 181 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers) and Breast Cancer Treatment Studies (3 papers). The work is most often cited by research in Oncology (102 citations), Cancer Research (31 citations) and Pathology and Forensic Medicine (33 citations). Vinay Gudena has collaborated with scholars based in United States, Mexico and South Africa. Frequent co-authors include Nitin Verma, Uzair B. Chaudhary, Terence T. Sio, Neal J. Meropol, Joseph Gibbons, Joel Saltzman, Joseph A. Bokar, John Lazarchick, Cheng Ean Chee and Mark Bergman. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026